Abstract

Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration

Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1091-1096.doi: 10.1080/17474124.2021.1898944. Epub 2021 Mar 10.

Deepa Denesh 1, Jenelyn Carbonell 1, John S Kane 1, David Gracie 1 2, Christian P Selinger 1 2

 
     

Author information

  • 1Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

2Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK

Abstract

Objectives: With increasing treatment choices for inflammatory bowel disease (IBD), patients' preferences should be considered to limit non-adherence. We explored patients' preferences for route, form and frequency of medication administration, and factors influencing these choices.Methods: Patients rated acceptability of different forms of medication on 10-point Likert scales and preferences for highest acceptable frequency.Results: Of 298 patients significantly more found tablets (91%) to be highly acceptable compared to granules (64%), infusions (33%) and subcutaneous injections (34%; p < 0.0001). The acceptable frequency for tablets was considered as daily by 63.5% and several times daily by 32.3%. Participants preferred nurse delivered over self-administered injections (median score 8 vs 5, p < 0.0001) and hospital-based infusions over infusions at home (median score 7 vs 5, p = 0.001). Patients with previous or current anti-TNF exposure were more accepting of self-administered injections (50.5% vs 23.3% anti-TNF naive; p < 0.001), more accepting of home based infusions (43.7% vs 28.0%; p = 0.001) and more accepting of hospital-based infusions (57.2% vs 37.8%; p = 0.02).Conclusion: Most patients with IBD prefer tablets. Those patients who already experienced biological agents, had a high level of acceptance for subcutaneous and intravenous forms of medication.

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.